CRL Cites Issues Related to Compatibility of Vials and Lenacapavir Solution No New Clinical Studies Requested in the CRL FOSTER CITY, Calif.–(BUSINESS WIRE)–Mar. 1, 2022– Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food…Original Article
Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatibility Issues
